Smoking Cessation in Elderly Patients

First-Line Treatment Options

Combination nicotine replacement therapy (nicotine patch plus a short-acting form like gum or lozenge) achieves the highest cessation rates at approximately 31.5% in elderly patients, significantly outperforming single-agent therapy, according to the American Heart Association 1
The American College of Cardiology recommends NRT as a preferred first-line treatment for elderly patients attempting smoking cessation, with varenicline as an equally effective alternative if there are no contraindications 1
NRT is particularly safe in elderly patients with cardiovascular disease, including those with established coronary heart disease, as stated by the American Heart Association 2
Long-term nicotine patch therapy (>14 weeks) is superior to shorter-term treatment and should be considered for extended use (6 months to 1 year) in elderly patients, as recommended by the Mayo Clinic 3, 1
Blood nicotine levels from NRT, even combination therapy, are significantly lower than from smoking cigarettes, making nicotine toxicity rare and transient, according to the National Comprehensive Cancer Network 4

Varenicline achieves approximately 28% cessation rates compared to 12% with placebo in elderly patients, as reported by the American Heart Association 1
Standard dosing for varenicline is 0.5 mg once daily for days 1-3, then 0.5 mg twice daily for days 4-7, then 1 mg twice daily for 12 weeks, according to the National Comprehensive Cancer Network 4, 1
However, varenicline requires specific cautions in elderly patients, including avoiding use in those with brain metastases or seizure risk, and monitoring carefully for neuropsychiatric symptoms, as recommended by the National Comprehensive Cancer Network 4, 5

Bupropion SR achieves approximately 19% cessation rates versus 11% with placebo in elderly patients, as reported by the American Heart Association 1
Bupropion should be avoided in elderly patients with seizure risk, as stated by the National Comprehensive Cancer Network 4, 1
Consider bupropion plus NRT combination if initial therapy with combination NRT or varenicline fails, as recommended by the National Comprehensive Cancer Network 5

Initial therapy for elderly patients should be either combination NRT (21 mg patch plus short-acting form like 2-4 mg gum or lozenge) for 12 weeks minimum or varenicline 1 mg twice daily for 12 weeks (if no contraindications), as recommended by the National Comprehensive Cancer Network 4, 1
For treatment failure or relapse, switch to varenicline if combination NRT failed, or switch to combination NRT plus bupropion if varenicline failed, as recommended by the National Comprehensive Cancer Network 5

All pharmacotherapy must be combined with behavioral counseling to maximize effectiveness, increasing cessation rates from 18% to 21% in elderly patients, as reported by the American Heart Association 1
A minimum of 4 sessions over 12 weeks is preferred, though even brief counseling (>3 minutes) provides benefit, according to the Mayo Clinic 6, 7

NRT and varenicline are safe in elderly patients with cardiovascular disease, including those with established coronary disease, as stated by the American Heart Association 2
The benefits of smoking cessation (25-50% reduction in mortality after MI) far outweigh any theoretical medication risks, according to the American Heart Association 2

The American College of Cardiology recommends varenicline or combination nicotine replacement therapy (NRT) as the primary treatment options for smoking cessation, with varenicline achieving nearly 3-fold higher quit rates compared to placebo 8
Varenicline increases smoking cessation odds by 2.88-fold versus placebo (95% CI: 2.40-3.47) 8
Varenicline is superior to bupropion with an odds ratio of 1.59 (95% CI: 1.29-1.96) 8
Varenicline is superior to single-form NRT with an odds ratio of 1.57 (95% CI: 1.29-1.91) 8

Common side effects of varenicline include nausea (28-29%), insomnia (14%), and abnormal dreams (10-13%) 8
Most adverse effects of varenicline are dose-dependent, so lower doses may eliminate side effects while retaining efficacy 9
NRT is safe even in patients with cardiovascular disease, including acute coronary syndromes 10, 11
Blood nicotine levels from NRT are significantly lower than from smoking cigarettes 11
No evidence that NRT causes cancer in humans or increases cardiovascular risk 8, 10

Varenicline standard dosing is 0.5 mg once daily for days 1-3, 0.5 mg twice daily for days 4-7, and 1 mg twice daily from day 8 onwards for a minimum of 12 weeks 9
Consider extended treatment duration (additional 12 weeks) for patients who achieve initial abstinence 8

Varenicline is effective for gradual smoking reduction in patients unwilling to quit but willing to reduce consumption 8
Additional 12 weeks of varenicline after initial successful quit helps sustain continued abstinence 8